StockData

Caribou Biosciences vs Taysha Gene Therapies

CRBU and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRBU and TSHA compare

Taysha Gene Therapies is the larger company, worth 36 times as much as Caribou Biosciences ($1.3B against $36.5M).

Caribou Biosciences grew revenue faster over the last twelve months (10.0% versus −32.3% for Taysha Gene Therapies).

Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1030% compared with −2728% at Taysha Gene Therapies.

Caribou Biosciences scores higher on the StockData Score (9 against 5 for Taysha Gene Therapies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRBUTSHA
Size and price
Market cap$36.5M$1.3B
Share price$0.341$4.00
Change, 1 year−82.9%−3.1%
Change, 5 years−98.1%−68.5%
Beta (5Y)1.412.80
Employees9799
StockData Score
Total score9 (better)5
Valuation score3 (better)0
Growth score11
Performance score01 (better)
Health score5 (better)3
Dividend score00
Valuation
P/S3.6× (better)238×
P/B0.4× (better)3.4×
FCF yield−262%−10.2% (better)
Fair value$1.29–
Margin of safety73.7%–
Growth
Revenue growth (TTM)10.0% (better)−32.3%
Revenue growth, 5Y average−2.0%–
Profitability
Operating margin−1091% (better)−2792%
Net margin−1030% (better)−2728%
FCF margin−954% (better)−2417%
Return on equity−78.3%−47.1% (better)
Financial health
Debt / equity0.000.13 (better)
Interest coverage–−3646.6×
Current ratio6.4917.76 (better)
Altman Z-score−7.477.07 (better)
Piotroski F-score25 (better)
Dividends and buybacks
Buyback yield−66.3%–
Shareholder yield−66.3%0.00% (better)
Ownership
Held by institutions45.5%91.9%
Held by insiders5.7%10.7%
Insider net buying, 12 months−$47.5K (better)−$6.1M
Short interest, % of float14.7%18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.